Nanobiotix (NASDAQ:NBTX) Trading 7.2% Higher – Time to Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares were up 7.2% on Tuesday . The stock traded as high as $42.30 and last traded at $41.9590. 24,010 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 65,190 shares. The stock had previously closed at $39.15.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NBTX shares. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. UBS Group raised their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Guggenheim lifted their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Finally, Leerink Partners boosted their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.33.

Nanobiotix Stock Up 6.1%

The company has a 50-day simple moving average of $39.81 and a 200 day simple moving average of $31.79.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC bought a new stake in Nanobiotix in the 4th quarter valued at $390,000. Marshall Wace LLP bought a new position in shares of Nanobiotix during the 4th quarter worth about $220,000. Finally, Royal Bank of Canada raised its position in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.